MX2015003035A - Administracion de inhibidores de acetilcolinesterasa para mitigar la paralisis inducida por neurotoxinas y el bloqueo neuromuscular residual. - Google Patents

Administracion de inhibidores de acetilcolinesterasa para mitigar la paralisis inducida por neurotoxinas y el bloqueo neuromuscular residual.

Info

Publication number
MX2015003035A
MX2015003035A MX2015003035A MX2015003035A MX2015003035A MX 2015003035 A MX2015003035 A MX 2015003035A MX 2015003035 A MX2015003035 A MX 2015003035A MX 2015003035 A MX2015003035 A MX 2015003035A MX 2015003035 A MX2015003035 A MX 2015003035A
Authority
MX
Mexico
Prior art keywords
administration
neurotoxin
mitigate
neuromuscular blockade
subject
Prior art date
Application number
MX2015003035A
Other languages
English (en)
Inventor
Matthew R Lewin
Original Assignee
Ophirex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ophirex Inc filed Critical Ophirex Inc
Publication of MX2015003035A publication Critical patent/MX2015003035A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se dan a conocer métodos y estuches para tratar o reducir la probabilidad de insuficiencia respiratoria inducida por neurotoxinas en un individuo, por ejemplo, una víctima de envenenamiento neurotóxico. También se dan a conocer métodos para tratar o reducir la probabilidad de bloqueo neuromuscular residual en un individuo a quien se le ha administrado un bloqueador neuromuscular no despolarizante. Los métodos implican administrarle al individuo una dosis farmacéuticamente eficaz de un inhibidor de acetilcolinesterasa, en donde la administración no es a través de inyección. En algunas modalidades, se utiliza administración intranasal u ocular.
MX2015003035A 2012-09-10 2013-09-06 Administracion de inhibidores de acetilcolinesterasa para mitigar la paralisis inducida por neurotoxinas y el bloqueo neuromuscular residual. MX2015003035A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261743705P 2012-09-10 2012-09-10
US201361771750P 2013-03-01 2013-03-01
US201361824087P 2013-05-16 2013-05-16
US201361857032P 2013-07-22 2013-07-22
PCT/US2013/058640 WO2014039920A1 (en) 2012-09-10 2013-09-06 Administration of acetylcholinesterase inhibitors to mitigate neurotoxin-induced paralysis and residual neuromuscular blockade

Publications (1)

Publication Number Publication Date
MX2015003035A true MX2015003035A (es) 2015-09-21

Family

ID=50237663

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015003035A MX2015003035A (es) 2012-09-10 2013-09-06 Administracion de inhibidores de acetilcolinesterasa para mitigar la paralisis inducida por neurotoxinas y el bloqueo neuromuscular residual.

Country Status (8)

Country Link
US (1) US20150224094A1 (es)
EP (1) EP2892521A4 (es)
AU (1) AU2013312240A1 (es)
CA (1) CA2884566A1 (es)
IN (1) IN2015KN00702A (es)
MX (1) MX2015003035A (es)
WO (1) WO2014039920A1 (es)
ZA (1) ZA201501561B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2640391B1 (en) 2010-11-15 2015-11-11 Agenebio, Inc. Pyridazine derivatives, compositions and methods for treating cognitive impairment
WO2015095783A1 (en) 2013-12-20 2015-06-25 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
MA40998A (fr) 2014-11-21 2017-09-26 Ophirex Inc Thérapies contre une envenimation, ainsi que compositions, systèmes et kits pharmaceutiques associés
JP6987384B2 (ja) 2015-06-19 2021-12-22 エージンバイオ， インコーポレイテッド ベンゾジアゼピン誘導体、組成物、および認知障害を処置するための方法
IL307232A (en) * 2016-04-29 2023-11-01 Ophirex Inc PLA2 and HMG-COA suppressors for the treatment of pathological diseases that cause hemolysis, brain edema and acute kidney injury
CA3023408A1 (en) * 2016-05-13 2017-11-16 DelNova, Inc. Treating of side-effects resulting from chemodenervation
US11505555B2 (en) 2016-12-19 2022-11-22 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US20180170941A1 (en) 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
KR20200105814A (ko) * 2017-11-15 2020-09-09 델노바 인코퍼레이티드 보툴리눔 요법의 부작용 치료
BR112020026062B1 (pt) 2018-06-19 2023-04-04 Agenebio, Inc Compostos derivados de benzodiazepina ou um sal farmaceuticamente aceitavel, isômero ou combinação dos mesmos, composição farmacêutica compreendendo os mesmos e usos dos mesmos para o tratamento de comprometimento cognitivo, câncer cerebral e psicose da doença de parkinson
CN114931551B (zh) * 2022-05-11 2023-04-25 四川科瑞德制药股份有限公司 一种25℃储存稳定的米库氯铵注射液及其制备方法和用途
WO2024039886A1 (en) 2022-08-19 2024-02-22 Agenebio, Inc. Benzazepine derivatives, compositions, and methods for treating cognitive impairment

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4060652A (en) * 1976-05-26 1977-11-29 Khromov Borisov Nikolai Vasili Nondepolarizing muscle relaxant
JP3923099B2 (ja) * 1995-06-05 2007-05-30 帝人株式会社 経鼻解毒剤
AU2003298514A1 (en) * 2002-05-17 2004-05-04 Eisai Co., Ltd. Methods and compositions using cholinesterase inhibitors
US20030225031A1 (en) * 2002-05-21 2003-12-04 Quay Steven C. Administration of acetylcholinesterase inhibitors to the cerebral spinal fluid
WO2005027905A1 (en) * 2003-09-19 2005-03-31 The Secretary Of State For Defence Pharmaceutical compositions for the treatment of organophosphate poisoning
EP1684753A2 (en) * 2003-10-28 2006-08-02 Cornell Research Foundation, Inc. Neuromuscular blocking agents and antagonists thereof

Also Published As

Publication number Publication date
IN2015KN00702A (es) 2015-07-17
CA2884566A1 (en) 2014-03-13
US20150224094A1 (en) 2015-08-13
AU2013312240A1 (en) 2015-03-19
ZA201501561B (en) 2016-10-26
EP2892521A4 (en) 2016-06-29
WO2014039920A1 (en) 2014-03-13
EP2892521A1 (en) 2015-07-15

Similar Documents

Publication Publication Date Title
MX2015003035A (es) Administracion de inhibidores de acetilcolinesterasa para mitigar la paralisis inducida por neurotoxinas y el bloqueo neuromuscular residual.
MX2021004821A (es) Uso de antagonistas contra muerte programada 1 (pd-1) y ligando de muerte programada 1 (pd-l1) en combinacion con radioterapia.
MX2016001793A (es) Terapia de combinacion para el tratamiento del cancer.
NZ748451A (en) Methods for treating atopic dermatitis by administering an il-4r antagonist
MX363601B (es) Ésteres de glicopirrolato anticolinérgico para el tratamiento de hiperhidrosis.
PH12018501903A1 (en) Methods of treating depression using orexin-2 receptor antagonists
MX2018013715A (es) Composiciones acuosas de capsaicinoides que comprenden un analgesico y un vehiculo acuoso, y uso de las mismas para el tratamiento del dolor.
WO2015095834A3 (en) Cancer treatments using erk1/2 and bcl-2 family inhibitors
MX2016002479A (es) Uso de inhibidores de acetil-coa carboxilasa para tratar acne vulgaris.
MX2016002580A (es) Combinacion de un inhibidor de alk y un inhibidor de cdk para el tratamiento de enfermedades celulares proliferativas.
MX2016006179A (es) Formulaciones de capsaicinoides basadas en agua y metodos de manufactura y uso.
SG10201810404XA (en) Combination comprising a glucocorticoid and edo-s101
MX350463B (es) Métodos de tratamiento del dolor.
MX359770B (es) Terapia de combinacion de un inhibidor de mek e inhibidor de igf1r.
MX2019008817A (es) Formulacion de liberacion prolongada para reducir la frecuencia de miccion y metodo de uso de la misma.
WO2016025671A3 (en) Treatment of sleep apnea with a combination of a carbonic anhydrase inhibitor and an aldosterone antagonist
MY195767A (en) Treatment of Androgen Deprivation Therapy Associated Symptoms
EA201170970A1 (ru) Применение деферипрона для лечения и предупреждения заболеваний глаз, связанных с железом
MX2016006256A (es) Tratamiento de glaucoma usando laquinimod.
MX370451B (es) Cloruro de dietil-[6-(4-hidroxicarbamoil-fenil-carbamoiloxi metil)-naftalen-2-il-metil]-amonio para su uso en el tratamiento de distrofia muscular.
MX337593B (es) Gemcabeno y derivados para tratar la pancreatitis.
MY198069A (en) Method for preventing or treating autism spectrum disorders by benzoic acid salt
WO2014023869A3 (es) Aplicacion terapéutica de agentes inhibidores de cd44 frente a la leucemia linfoblástica aguda (all) humana
WO2013172923A8 (en) Uses of antagonists of hyaluronan signaling
MX2016011002A (es) Tratamiento de angioedema hereditario con inhibidor c1.